Last reviewed 2026-04-19 · How we verify

Omiganan 2.5% and Imiquimod

Maruho Co., Ltd. · Phase 1 active Small molecule

Omiganan 2.5% and Imiquimod is a Small molecule drug developed by Maruho Co., Ltd.. It is currently in Phase 1 development.

At a glance

Generic name	Omiganan 2.5% and Imiquimod
Sponsor	Maruho Co., Ltd.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Topical Challenge With Omiganan and Imiquimod in Healthy Volunteers (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Omiganan 2.5% and Imiquimod CI brief — competitive landscape report
Omiganan 2.5% and Imiquimod updates RSS · CI watch RSS
Maruho Co., Ltd. portfolio CI

Frequently asked questions about Omiganan 2.5% and Imiquimod

What is Omiganan 2.5% and Imiquimod?

Omiganan 2.5% and Imiquimod is a Small molecule drug developed by Maruho Co., Ltd..

Who makes Omiganan 2.5% and Imiquimod?

Omiganan 2.5% and Imiquimod is developed by Maruho Co., Ltd. (see full Maruho Co., Ltd. pipeline at /company/maruho-co-ltd).

What development phase is Omiganan 2.5% and Imiquimod in?

Omiganan 2.5% and Imiquimod is in Phase 1.

Manufacturer: Maruho Co., Ltd. — full pipeline
Compare: Omiganan 2.5% and Imiquimod vs similar drugs
Pricing: Omiganan 2.5% and Imiquimod cost, discount & access